Changeflow GovPing Pharma & Drug Safety Patent Application: Cytotoxic Lymphocyte Activa...
Routine Notice Added Draft

Patent Application: Cytotoxic Lymphocyte Activation and Expansion

Email

Summary

The USPTO has published patent application US20260083776A1 concerning methods for activating and expanding cytotoxic lymphocytes with decreased exhaustion potential. The application details micropatterned surfaces and biofunctionalization techniques for cell expansion, potentially impacting future therapeutic development in oncology.

What changed

This document is a published patent application (US20260083776A1) from the USPTO detailing novel micropatterned surfaces and methods for activating and expanding cytotoxic lymphocytes. The invention aims to reduce cell exhaustion and has potential applications in treating patients. The application was filed on September 5, 2023, and published with a projected date of March 26, 2026.

While patent applications are not regulations, they signal potential future innovations and areas of research that may eventually lead to new therapies or require regulatory oversight. Companies involved in cell therapy, immunotherapy, and oncology research should be aware of this disclosure as it may influence future product development and intellectual property landscapes in the pharmaceutical and biotechnology sectors.

Source document (simplified)

← USPTO Patent Applications

ACTIVATION AND PROLIFERATION OF CYTOTOXIC LYMPHOCYTES

Application US20260083776A1 Kind: A1 Mar 26, 2026

Inventors

Mark SCHVARTZMAN, Angel PORGADOR, Ashish PANDEY, Carlos Ureña MARTIN, Guillaume LE SAUX

Abstract

Disclosed herein are micropatterned surfaces, particularly in the shape of micro-brushes having a base and a plurality of elongated elements. The micropatterned surfaces suitably biofunctionalized are particularly useful for activation and expansion of cells. Methods for activation and expansion of cytotoxic lymphocytes with decreased exhaustion potential are also provided, as well as means involving same to treat a patient in need thereof.

CPC Classifications

A61K 35/17 A61K 40/11 A61K 40/31 A61P 35/00 C12N 5/0018 C12N 5/0638 C12N 9/226 C12N 15/111 C12N 15/87 C12N 2310/20 C12N 2501/2301 C12N 2501/2302 C12N 2501/2304 C12N 2501/2306 C12N 2501/2307 C12N 2501/231 C12N 2501/2312 C12N 2501/2315 C12N 2501/2318 C12N 2501/25 C12N 2501/51 C12N 2501/515 C12N 2510/00 C12N 2533/30 C12N 2533/50 C12N 2535/10

Filing Date

2023-09-05

Application No.

19108842

View original document →

Named provisions

Abstract

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083776A1
Docket
19108842

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Cell Therapy Immunotherapy
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Research & Development
Topics
Pharmaceuticals Biotechnology

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.